Gamida Cell rises on pursuit of asset sale or merger

Gamida Cell

29/01/2024 11:41

** U.S.-listed shares of Israel-based cell therapy developer
Gamida Cell  GMDA.O  rise ~12.5% to 41 cents premarket 
    ** Co says it is actively focusing on an asset sale, merger
or other strategic transaction to maximize stakeholder value
    ** Says it continues to focus on the commercialization of
Omisirge, its cell therapy for a type of blood cancer 
    ** As of last close, stock down 77.2% in the last 12 months 

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))